MicroRNA 378e (miR-378e)

MicroRNA 378e (miR-378e) is a member of the microRNA-378 family, classified as a non-coding, regulatory RNA molecule involved in the post-transcriptional regulation of gene expression[1]. Like other microRNAs, it is ~20-24 nucleotides in length and primarily functions by binding target mRNAs within the RNA-induced silencing complex (RISC), leading to mRNA degradation or translational inhibition[1]. miR-378e participates in diverse biological processes, particularly in regulation of cardiovascular physiology and pathology, modulating cell growth, apoptosis, mitochondrial metabolism, fibrosis, angiogenesis, and cellular response to hypoxia[2]. Elevated or diminished levels of circulating miR-378e are associated with various cardiovascular conditions (e.g., coronary heart disease, heart failure, myocardial infarction), and there is emerging evidence linking altered miR-378e expression to cancer, notably in tumor classification and progression in breast cancer[2][3]. It is increasingly studied as a potential biomarker for disease progression and prognosis, especially in heart disease and oncology, but as a non-protein-coding RNA, it is not conventionally considered a direct therapeutic "target" like receptors, enzymes, or transporters[1][2][3]. Key context: - miR-378e is one of several paralogs (e.g., miR-378a, -b, -c, -d, -e, etc.), sharing a common seed sequence but encoded at distinct genomic loci[2]. - It exerts cardioprotective effects in models of heart disease, modulating pathways such as MAPK, Smad2/3, and targeting genes like MAPK6 and MT-ATP6[2]. - In breast cancer and other contexts, miR-378e may serve as a marker for cell type or tumor subtype, and is differentially expressed in stromal versus normal fibroblast exosomes[3]. - Current literature does not identify direct drug interactions or established mechanisms of drug action via miR-378e, but modulation of its levels is under investigation as a therapeutic approach in preclinical studies[2][3]. - As a microRNA, safety concerns relate to potential off-target effects or broad regulatory impacts if used therapeutically, but such information is not reported specifically for miR-378e. Sources: [1] GeneCards (MIR378E RNA Gene - GeneCards) [2] PMC10436248 (MicroRNA-378: An important player in cardiovascular diseases) [3] PMC8582384 (MicroRNAs in Molecular Classification and Pathogenesis of Breast Cancer)

Other names

hsa-mir-378emir-378eMIR378EmicroRNA 378e